[ U.S. CDMRP - ALS Therapeutic Development Award | Research Funding ]
Event details
| Date | 09.04.2021 |
| Category | Call for proposal |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the Amyotrophic Lateral Sclerosis (ALS) Research Program Therapeutic Development Award. supports research ranging from validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applications supported by this award must begin with lead compounds in hand and must include preliminary data relevant to the phase of development (e.g .Proof of identity and purity, Selectivity for the intended target over closely related targets Availability of primary and secondary in vitro bioactivity assays for optimization or structure-activity relationship studies. Availability of proof-of-concept efficacy data in at least one preclinical model system of ALS, including whole animal and cellular model systems)
Development or further characterization of validated biomarkers, in parallel to the main therapeutic effort and for use in eventual clinical trials, is a critical component of the FY21. Efforts may include development/characterization of target engagement biomarkers, pharmacodynamic biomarkers to measure the biological effect of an investigational therapeutic, and/or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual patient or patient subgroup
Funding: max. $1’000’000
Duration: 3 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Applicants must be independent investigators, but can come from any academic level.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a list of collaborators and key personnel, a preproposal narrative, and supporting documentation as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 5:00 p.m. Eastern time (ET), April 9, 2021.
Full Application Deadline: 11:59 p.m. ET, July 15, 2021
Grants.gov Funding Opportunity Number: W81XWH-21-ALSRP-TDA
Further information
Development or further characterization of validated biomarkers, in parallel to the main therapeutic effort and for use in eventual clinical trials, is a critical component of the FY21. Efforts may include development/characterization of target engagement biomarkers, pharmacodynamic biomarkers to measure the biological effect of an investigational therapeutic, and/or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual patient or patient subgroup
Funding: max. $1’000’000
Duration: 3 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Applicants must be independent investigators, but can come from any academic level.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a list of collaborators and key personnel, a preproposal narrative, and supporting documentation as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 5:00 p.m. Eastern time (ET), April 9, 2021.
Full Application Deadline: 11:59 p.m. ET, July 15, 2021
Grants.gov Funding Opportunity Number: W81XWH-21-ALSRP-TDA
Further information
- To see the program announcement, navigate to the search page on Grants.gov and search for the Opportunity Number W81XWH-21-ALSRP-TDA
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
Practical information
- General public
- Free